Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 501–600 of 3,636
Turgeon, R. D., Tsuyuki, R. T., Gyenes, G. T., & Pearson, G. J. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.04.002 · Cited by 43
Hollan, I., Ronda, N., Dessein, P. H., Agewall, S., Karpouzas, G. A., Tamargo, J. L., Niessner, A., Savarese, G., Rosano, G. M. C., Kaski, J. C., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz033 · Cited by 48
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kasner, M., Hassanein, A., Friebel, J., & Rauch-Kröhnert, U. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 43
“98; Table 2, Figure 2); however, this endpoint was not tested statistically, due to the hierarchical testing plan [14].”
BackgroundMethodInfluentialDi Minno, A., Gentile, M., Iannuzzo, G., Calcaterra, I., Tripaldella, M., Porro, B., Cavalca, V., Di Taranto, M. D., Tremoli, E., Fortunato, G., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.07.049 · Cited by 45
Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence
Camerino, G. M., Tarantino, N., Canfora, I., Bellis, M. D., Musumeci, O., & Pierno, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042070 · Cited by 53
Zanchin, C., Koskinas, K. C., Ueki, Y., Losdat, S., Häner, J. D., Bär, S., Otsuka, T., Inderkum, A. P., Jensen, M. D. R. J., Lønborg, J., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.04.006 · Cited by 43
The role of PCSK9 in inflammation, immunity, and autoimmune diseases
Frostegård, J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2017281 · Cited by 43
Xu, J., Hao, X., Zhan, R., Jiang, X., Jin, A., Xue, J., Cheng, A., Liu, J., Lin, J., Meng, X., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.034924 · Cited by 45
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
“It can also be concluded that previous studies have not shown that therapy with a PCSK9 inhibitor has a harmful effect on cognitive functions [51,52].”
ResultDe Filippo, O., D’Ascenzo, F., Iannaccone, M., Bertaina, M., Leone, A., Borzillo, I., Ravetti, E., Solano, A., Pagliassotto, I., Nebiolo, M., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02022-z · Cited by 43
“The reduction in MACE found in the most important contributor of this meta-analysis, the CLEAR OUTCOME study is similar to that observed in the composite primary endpoint of the two recent PCSK9i outcome studies [33, 37].”
ResultKoren, M. J., Descamps, O., Hata, Y., Hengeveld, E. M., Hovingh, G. K., Ikonomidis, I., Radu Juul Jensen, M. D., Langbakke, I. H., Martens, F. M. A. C., Søndergaard, A. L., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00325-x · Cited by 43
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 43
Self-citationAlirocumab after acute coronary syndrome in patients with a history of heart failure
White, H. D., Schwartz, G. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab804 · Cited by 41
Self-citationLDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?
Ferhatbegović, L., Mršić, D., Kušljugić, S., & Pojskić, B. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01037-3 · Cited by 44
Nicholls, S. J., Nelson, A. J., Lincoff, A. M., Brennan, D. M., Ray, K. K., Cho, L., Menon, V., Li, N., Bloedon, L. T., & Nissen, S. E. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5155 · Cited by 56
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease: Lessons From the COMPASS Trial
Coppens, M., Weitz, J. I., & Eikelboom, J. W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313141 · Cited by 45
Kramer, A. I., Trinder, M., & Brunham, L. R. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.06.017 · Cited by 53
Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial
Turan, T. N., Voeks, J. H., Chimowitz, M. I., Roldan, A., LeMatty, T., Haley, W. E., Lopes-Virella, M. F., Chaturvedi, S., Jones, M. R., Heck, D. V., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.030730 · Cited by 43
Cammisotto, V., Baratta, F., Castellani, V., Bartimoccia, S., Nocella, C., D’Erasmo, L., Cocomello, N., Barale, C., Scicali, R., Pino, A. D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137193 · Cited by 45
“In several clinical studies, the PCSK9i, alirocumab, and evolocumab, have been shown to improve atherosclerosis [5,6] and prevent cardiovascular events [7,8].”
BackgroundGao, F., Wang, Z. J., Ma, X., Shen, H., Yang, L., & Zhou, Y. J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01528-3 · Cited by 45
Lee, C., Park, J. T., Chang, T. I., Kang, E. W., Nam, K. H., Joo, Y. S., Sung, S. A., Kim, Y. H., Chae, D., Park, S. K., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.037 · Cited by 46
“Notably, recent trials with proprotein convertase subtilisin/kexin type 9 inhibitors have shown that lowering LDLC to <50 mg/dL reduces major adverse cardiovascular events (MACEs) in patients with high cardiovascular risk who receive maximal statin therapy [4,5].”
BackgroundVirani, S. S., Aspry, K. E., Dixon, D. L., Ferdinand, K. C., Heidenreich, P. A., Jackson, E. J., Jacobson, T. A., McAlister, J. L., Neff, D., Gulati, M., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.02.003 · Cited by 49
Mitani, H., Suzuki, K., Ako, J., Iekushi, K., Majewska, R., Touzeni, S., & Yamashita, S. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63940 · Cited by 52
PCSK9 Inhibitors: The Evolving Future
Jeswani, B. M., Sharma, S., Rathore, S. S., Nazir, A., Bhatheja, R., & Kapoor, K. (2024) · Health Science Reports · doi:10.1002/hsr2.70174 · Cited by 49
Casula, M., Olmastroni, E., Boccalari, M. T., Tragni, E., Pirillo, A., & Catapano, A. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.021 · Cited by 46
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Tindall, A. M., Kris‐Etherton, P. M., & Petersen, K. S. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz313 · Cited by 45
Donato, M., Ferri, N., Lupo, M. G., Faggin, E., & Rattazzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218263 · Cited by 53
“Recently, the ODYSSEY OUTCOMES trial has detected a reduction in the risk of major adverse CV events after addition of alirocumab to background statin therapy in patients with recent acute coronary syndrome [83], confirming the additional beneficial effect of this lipid-lowering therapy.”
BackgroundColesterol LDL y aterosclerosis: evidencias
Guijarro, C., & Cosín-Sales, J. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.004 · Cited by 67
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
“An analysis of clinical trials (FOURIER and ODYSSEY OUTCOMES) reported lower rates of venous thromboembolism in patients who were treated with PCSK9 inhibitors compared with placebo [207,208].”
MethodLp(a): a New Pathway to Target?
Nurmohamed, N. S., Kraaijenhof, J. M., & Stroes, E. S. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01060-4 · Cited by 48
Gunta, S. P., O’Keefe, J. H., O’Keefe, E. L., & Lavie, C. J. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.02.007 · Cited by 45
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
“Similarly, in the Evaluation of Cardiovascular outcomes after Acute coronary syndrome during treatment with Alirocumab (ODYSSEY Outcomes), despite achieving LDL-C as low as 1.7 mmol/L (66 mg/dl), probability estimate of alirocumab recipients to have ASCVD event was 12.8% at 4 years (15).”
ResultInfluentialSchwartz, G. G., Szarek, M. J., Bittner, V., Bhatt, D. L., Díaz, R., Goodman, S. G., Jukema, J. W., Loy, M., Manvelian, G. Z., Pordy, R. C., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2842 · Cited by 42
Self-citationSex difference in circulating PCSK9 and its clinical implications
Jia, F., Fei, S.-F., Tong, D.-B., Xue, C., & Li, J.-J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.953845 · Cited by 40
The evolving landscape of PCSK9 inhibition in cancer
Oza, P. P., & Kashfi, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175721 · Cited by 44
Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction
Biccirè, F. G., Kakizaki, R., Koskinas, K. C., Ueki, Y., Häner, J. D., Shibutani, H., Lønborg, J., Spitzer, E., Iglesias, J. F., Otsuka, T., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3200 · Cited by 43
Yoshiji, S., Lu, T., Butler‐Laporte, G., Carrasco-Zanini, J., Su, C., Chen, Y., Liang, K., Willett, J., Wang, S., Adra, D., et al. (2023) · Nature Genetics · doi:10.1016/j.cjca.2023.06.321 · Cited by 65
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00972-x · Cited by 46
Katzmann, J. L., Cupido, A. J., & Laufs, U. (2022) · Metabolites · doi:10.3390/metabo12010070 · Cited by 40
“Both the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) [15] and the ODYSSEY Outcomes study [16] demonstrated a 15% relative reduction in cardiovascular risk on top of statin therapy during 2.”
MethodOmega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials
Jia, X., Kohli, P., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0763-0 · Cited by 39
Real-world utilization of bempedoic acid in an academic preventive cardiology practice
Warden, B. A., Cardiology, B.-A., Purnell, J. Q., Duell, P. B., & Fazio, S. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.11.013 · Cited by 39
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Tardif, J., Pfeffer, M. A., Kouz, S., Köenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., Waters, D. D., Grégoire, J. C., L’Allier, P. L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac374 · Cited by 41
Self-citationPCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Carugo, S., Sirtori, C. R., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01074-y · Cited by 45
Williams, K. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320065 · Cited by 47
Ilahibaks, N. F., Kluiver, T. A., de Jong, O. G., de Jager, S. C. A., Schiffelers, R. M., Vader, P., Peng, W. C., Lei, Z., & Sluijter, J. P. G. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12389 · Cited by 44
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management
Patel, N., Mittal, N., Wilkinson, M. J., & Taub, P. R. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100666 · Cited by 47
Strategies to Overcome Residual Risk During Statins Era
Cho, K. I., Yu, J., Hayashi, T., Han, S. H., & Koh, K. K. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0624 · Cited by 42
Yamashita, S., Arai, H., Bujo, H., Masuda, D., Ohama, T., Ishibashi, T., Yanagi, K., Doi, Y., Nakagawa, S., Yamashiro, K., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.55327 · Cited by 42
Raygor, V., & Khera, A. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01331-z · Cited by 39
Li, Y.-H., Lee, C., Huang, W.-C., Wang, Y.-C., Su, C.-H., Sung, P., Chien, S.-C., & Hwang, J. (2020) · PubMed · doi:10.6515/acs.202007_36(4).20200619a · Cited by 43
PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
Andreadou, I., Tsoumani, M. E., Vilahur, G., Ikonomidis, I., Badimón, L., Varga, Z. V., Ferdinandy, P., & Schulz, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.602497 · Cited by 39
Zafrir, B., Egbaria, A., Stein, N., Elis, A., & Saliba, W. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.11.004 · Cited by 44
Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source
Tatuene, J. K., Nomani, A. Z., Falcione, S. R., Munsterman, D., Sykes, G. P., Joy, T., Spronk, E., Vargas, M. I., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.719329 · Cited by 41
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
“Moreover, several clinical trials assessing lipid-lowering drug combinations have shown greater ASCVD risk reduction maintaining LDL-C levels 25 mg/dL, without limiting safety concerns [84,85].”
BackgroundLandmesser, U., Pirillo, A., Farnier, M., Jukema, J., Laufs, U., Mach, F., Masana, L., Pedersen, T., Schiele, F., Steg, G., et al. (2020) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2021.01.009 · Cited by 32
Self-citationSmith, A., Johnson, D. M., Banks, J., Keith, S. W., & Karalis, D. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173828 · Cited by 38
“In large, randomized outcome studies in patients with clinical ASCVD, both evolocumab [2] and alirocumab [3] have demonstrated improved cardiovascular outcomes.”
BackgroundResultCammisotto, V., Baratta, F., Simeone, P., Barale, C., Lupia, E., Galardo, G., Santilli, F., Russo, I., & Pignatelli, P. (2022) · Antioxidants · doi:10.3390/antiox11030569 · Cited by 42
“Phase-3 interventional studies demonstrated that both alirocumab and evolocumab reduce cardiovascular events beyond the lipid-lowering effect of the PCSK9 inhibitors (PCSK9i) [18,19], inducing investigations into the so-called pleiotropic effects of inhibiting PCSK9.”
BackgroundPeterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022937 · Cited by 38
Self-citationLin, Y., Parco, C., Karathanos, A., Krieger, T., Schulze, V., Chernyak, N., Icks, A., Kelm, M., Brockmeyer, M., & Wolff, G. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048893 · Cited by 38
Ruscica, M., Macchi, C., Giuliani, A., Rizzuto, A. S., Ramini, D., Sbriscia, M., Carugo, S., Bonfigli, A. R., Corsini, A., Olivieri, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01948-8 · Cited by 45
“In addition, concerning these last (CV- and all-cause deaths), data from interventional trials (with monoclonal antibodies) [15, 16] or genetic studies (associating low LDL-C to PCSK9 variants) [17] are contrasting.”
BackgroundZisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“Resmetirom, a liver-targeted THR-β selective agonist, showing promising results in the improvement of hepatic fibrosis and MASH resolution, has recently received FDA approval for non-cirrhotic MASH patients with moderate to advanced fibrosis, along with dietary and exercise interventions [104].”
Contemporary Management of Stable Coronary Artery Disease
Bertolone, D. T., Gallinoro, E., Esposito, G., Paolisso, P., Bermpeis, K., Colle, C. D., Fabbricatore, D., Mileva, N. B., Valeriano, C., Munhoz, D., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00497-z · Cited by 52
“The IMPROVE-IT trial with the Ezetimibe, the FOURIER and ODISSEY trials with the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody therapies Evolocumab and Alirocumab, have shown an outstanding event-rate reduction directly related to the extreme reduction of LDL in patients with both chronic a…”
MethodOstadal, P., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V., Chua, T., Díaz, R., Goodman, S. G., Huo, Y., Jukema, J. W., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00043-2 · Cited by 44
Self-citationAeschbacher‐Germann, M., Kaiser, N., Speierer, A., Blum, M. R., Bauer, D. C., Giovane, C. D., Aujesky, D., Gencer, B., Rodondi, N., & Moutzouri, E. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026551 · Cited by 46
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels
Scientific Board of GLAR for the German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Hohenstein, B., Roeseler, E., Heigl, F., Grützmacher, P., et al. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00094-4 · Cited by 37
The Role of C-reactive Protein in Patient Risk Stratification and Treatment
Arroyo‐Espliguero, R., Viana-Llamas, M. C., Silva, J. A., & y, P. A. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.49 · Cited by 46
PCSK9 inhibitors: current status and emerging frontiers in lipid control
Agnello, F. G., Mauro, M. S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P. M., Spagnolo, M., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2288169 · Cited by 45
“Large-scale pivotal clinical trials in high-risk patients have demonstrated that these mAbs can lower plasma LDL-C levels by approximately 60% and are associated with a 15% relative risk reduction in long-term cardiovascular outcomes [37,38].”
BackgroundVitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes
Nardin, M., Verdoia, M., Nardin, S., Cao, D., Chiarito, M., Kedhi, E., Galasso, G., Condorelli, G., & Luca, G. D. (2024) · Biomedicines · doi:10.3390/biomedicines12040768 · Cited by 49
“Therefore, there is a need for further research to explore new risk factors [13–17] and therapies [18] in coronary artery disease (CAD).”
BackgroundChinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 42
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Nicholls, S. J., Nelson, A. J., Ray, K. K., Ballantyne, C. M., Ditmarsch, M., Kling, D. F., Hsieh, A., Szarek, M. J., Kastelein, J. J. P., & Davidson, M. H. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.056 · Cited by 44
Self-citationAscaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.002 · Cited by 51
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
Koskinas, K. C., Gencer, B., Nanchen, D., Branca, M., Carballo, D., Klingenberg, R., Blum, M. R., Carballo, S., Müller, O., Matter, C. M., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320940102 · Cited by 43
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 41
Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 46
The year in cardiology 2018: prevention
Reiner, Ž., Laufs, U., Cosentino, F., & Landmesser, U. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy894 · Cited by 49
Mechanistic Insights to Target Atherosclerosis Residual Risk
Alkhalil, M. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.06.004 · Cited by 39
Reijman, M. D., Schweizer, A., Peterson, A. L. H., Bruckert, E., Stratz, C., Defesche, J. C., Hegele, R. A., & Wiegman, A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac025 · Cited by 37
Altabas, V., & Biloš, L. S. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052663 · Cited by 37
“Furthermore, a significant reduction in cardiovascular risk was demonstrated for alirocumab and evolocumab in large international blinded randomized trials [112,113].”
BackgroundZou, Y., Chen, Z., Zhang, X., Yu, J., Xu, H., Cui, J., Li, Y., Niu, Y., Zhou, C., Xia, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894789 · Cited by 37
“, Evolocumab and alirocumab) on reducing the occurrence of cardiovascular events (6, 7).”
BackgroundThe critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress
Bale, B. F., Doneen, A. L., Leimgruber, P. P., & Vigerust, D. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1042729 · Cited by 40
Fowler, A., Rompay, K. K. A. V., Sampson, M. L., Leo, J., Watanabe, J., Usachenko, J. L., Immareddy, R., Lovato, D. M., Schiller, J. T., Remaley, A. T., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00743-6 · Cited by 43
“Evolocumab (Repatha ® ) and alirocumab (Pralu-ent ® ) are anti-PCSK9 mAbs that lower LDL-C levels by as much as 50-60% 16 – 18 .”
Dutka, M., Zimmer, K., Ćwiertnia, M., Ilczak, T. P., & Bobiński, R. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10409-7 · Cited by 48
“They also often spontaneously resolved themselves [16, 18].”
BackgroundMethodInfluentialComparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
Lincoff, A. M., Ray, K. K., Sasiela, W. J., Haddad, T. M., Nicholls, S. J., Li, N., Cho, L., Mason, D., Libby, P., Goodman, S. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.048 · Cited by 48
Self-citationNew evidence on the role of inflammation in CVD risk
Lorenzatti, A. J., & Servato, L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000625 · Cited by 42
Владиславович, Е. М., Bliznyuk, S. А., Tmoyan, N. A., Ta, R., Duplyakov, D. V., Сальченко, В. А., Kachkovsky, M. A., Иосифович, Ш. И., Genkel, V. V., Gurevich, V. S., et al. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-5-7-13 · Cited by 36
Luca, L. D., Arca, M., Temporelli, P. L., Meessen, J. M. T. A., Riccio, C., Bonomo, P., Colavita, A. R., Gabrielli, D., Gulizia, M. M., & Colivicchi, F. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.055 · Cited by 36
Bempedoic acid for the treatment of dyslipidemia
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 44
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Barkas, F., Milionis, H. J., Anastasiou, G., & Liberopoulos, E. N. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110452 · Cited by 38
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
Giovanni, G. D., & Nicholls, S. J. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100366 · Cited by 37
“Use of these agents were demonstrated to produce reductions in major adverse cardiovascular events when used in combination with statin therapy in patients with stable and unstable ischemic syndromes [47,48].”
BackgroundNew Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 39
“Adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to moderate- or high-intensity statin therapy regimens leads to cardiovascular risk reduction in patients with stable atherosclerotic cardiovascular disease, or after recent acute coronary syndromes [14,15].”
BackgroundSex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry
Galema‐Boers, A. M. H., Mulder, J. W. C. M., Steward, K., & van Lennep, J. E. R. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.013 · Cited by 39
Kim, J., Wilbon, S. S., & Fornoni, A. (2021) · Kidney360 · doi:10.34067/kid.0006152020 · Cited by 40
Montelukast and Acute Coronary Syndrome: The Endowed Drug
Alomair, B. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Al-Hamash, S. M., WAARD, M. M. D., Sabatier, J., Saad, H. M., & Batiha, G. E. (2022) · Pharmaceuticals · doi:10.3390/ph15091147 · Cited by 35
“Thrombolytic therapy is indicated for STEMI, while nitroglycerin, antiplatelet, low-molecular-weight heparin (LMWH) such as enoxaparin, and heparin-like drugs such as fondaparinux are effective in this state [6,7].”
BackgroundPCSK9 and the nervous system: a no-brainer?
Jaafar, A. K., Techer, R., Chemello, K., Lambert, G., & Bourane, S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100426 · Cited by 42
“But the analysis of larger groups of patients enrolled in those trials over longer follow-up periods did not show significantly more neurocognitive adverse events associated with these therapies (10, 84, 85).”
BackgroundBohula, E. A., Marston, N., Ruzza, A., Murphy, S. A., Ferrari, G. M. D., Díaz, R., Leiter, L. A., Elliott‐Davey, M., Wang, H., Bhatia, A. K., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.004 · Cited by 41
Self-citationGenetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk
Gobeil, É., Bourgault, J., Mitchell, P. L., Houessou, U., Gagnon, É., Girard, A. S., Paulin, A., Manikpurage, H. D., Côté, V., Couture, C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad845 · Cited by 37
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Garwood, C. L., Cabral, K. P., Brown, R., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4635 · Cited by 48
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

